Following discussions on ado-trastuzumab emtansine and fam-trastuzumab deruxtecan-nxki, Tanya Gupta, MD, discusses sacituzumab govitecan and its approval from the FDA in the breast cancer space.
Tanya Gupta, MD
Advertisement
Tanya Gupta, MD, is a medical oncologist in the Stanford University Department of Medicine, Division of Medical Oncology.
Articles by Tanya Gupta, MD
Tanya Gupta, MD, evaluates fam-trastuzumab deruxtecan-nxki and its role in breast cancer treatment.
Tanya Gupta, MD, discusses the use of ado-trastuzumab emtansine for the treatment of patients with HER2-positive breast cancer.
Tanya Gupta, MD, discusses the current landscape of antibody-drug conjugates for breast cancer subtypes beyond HER2-positive disease.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
